NR4A1 and neoplasm: Further refinement in risk stratification of eBC has been brought by gene-expression assays [11,12] which provide prognostic information by analyzing primary tumor tissues, and help in decisions regarding appropriate use of adjuvant chemotherapy in hormone receptor-positive/HER2-negative eBC.